Oligonucleotide (Antisense oligonucleotide) · developed by ASTRAZENECA
AZD2693 is a subcutaneously administered solution studied in nonalcoholic steatohepatitis, a liver disease related to nonalcoholic fatty liver disease and liver cirrhosis.
Summary written with AI from the sources listed at the end of this page.
Nonalcoholic Steatohepatitis
Updated Nov 1, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →